About 60,398 results
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk M...
Blood Jabbour E, Short NJ et. al.

Aug 4th, 2017 - Hypomethylating agents (HMAs) improve survival in patients with higher-risk myelodysplastic syndromes (MDS) but are less well-studied in lower-risk disease. We compared the safety and efficacy of low-dose decitabine vs low-dose azacitidine in this group of patients. Adults with low- or intermediate 1-risk MDS or MDS/myeloproliferative neoplasm (MPN), including chronic myelomonocytic leukemia, a...

Diffuse Large B-Cell Lymphoma: ESMO Clinical Practice Guidelines
Annals of Oncology; Tilly H et al

Nov 13th, 2019 - Diffuse large B-cell lymphoma is relatively common and represents 30%–58% of non-Hodgkin’s lymphomas. The updated ESMO Clinical Practice Guidelines provide information on the current management of diffuse large B-cell lymphoma including recommendations for screening and diagnosis, staging and risk assessment and stage-matched therapeutic strategies including specific recommendations for young a...

Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding: ACOG COMMITTEE OPINION, Number 785

Aug 21st, 2019 - Heavy menstrual bleeding is defined as excessive menstrual blood loss that interferes with a woman's physical, social, emotional, or material quality of life. If obstetrician–gynecologists suspect that a patient has a bleeding disorder, they should work in coordination with a hematologist for laboratory evaluation and medical management. Evaluation of adolescent girls who present with heavy men...

Use of Antibiotics and Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies
Cancers Petrelli, F. et. al.

Jul 30th, 2019 - The association between antibiotic use and risk of cancer development is unclear, and clinical trials are lacking. We performed a systematic review and meta-analysis of observational studies to assess the association between antibiotic use and risk of cancer. PubMed, the Cochrane Library and EMBASE were searched from inception to 24 February 2019 for studies reporting antibiotic use and subsequ...

AGA Guideline on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D)

Jul 10th, 2019 - This document presents the official recommendations of the American Gastroenterological Association (AGA) on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) in Adults. The guideline was developed by the AGA’s Clinical Practice Guideline Committee and approved by the AGA Governing Board. These Guidelines should expire in 5 years. The ...

Acute Myeloid Leukemia - AML | ARUPConsult Lab Test Selection

Jun 30th, 2019 - Acute myeloid leukemias (AMLs) are a heterogeneous group of disorders characterized by the clonal expansion of myeloid blasts (eg, undifferentiated myeloid precursors) in the peripheral blood, bone marrow, and/or other tissues, which results in impaired hematopoiesis and bone marrow failure. 1, 2, 3, 4 AML is the most common acute leukemia in adults (~80% of leukemia cases) and accounts for the...

Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network;

Jun 14th, 2019 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. Recent advances have resulted in an expansion of treatment options for AML, especially concerning targeted therapies and low-intensity regimens. This portion of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guid...

23rd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma

Feb 27th, 2019 - Now in its 23rd year, the annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma provides practitioners who manage hematologic malignancies the practical tools to translate emerging data into the best therapy for patients with these tumors, personalize care based upon patient and tumor characteristics, and apply novel management strategies to thei...

Cancer incidence in the Agricultural Health Study after 20 years of follow-up
Cancer Causes & Control; Lerro, C. et. al.

Feb 24th, 2019 - To evaluate cancer incidence in the Agricultural Health Study (AHS), a cohort of private pesticide applicators, their spouses, and commercial applicators, based on 12,420 cancers, adding 5,989 cancers, and 9 years of follow-up since last evaluation. Overall AHS cancer incidence was lower than the general population (SIRprivate = 0.91, CI 0.89–0.93; SIRspouse = 0.89, CI 0.86–0.92; SIRcommercial ...

Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas
Koch, R. et. al.

Feb 6th, 2019 - There is a pressing need for more effective therapies to treat patients with T-cell lymphomas (TCLs), including first-line approaches that increase the response rate to cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) chemotherapy. We characterized the mitochondrial apoptosis pathway in cell lines and patient-derived xenograft (PDX) models of TCL and assessed the in vitro effica...

FDA grants orphan drug designation to APL-2 for autoimmune hemolytic anemia

Feb 4th, 2019 - The FDA granted orphan drug designation to the C3 complement inhibitor APL-2 for the treatment of autoimmune hemolytic anemia. Autoimmune hemolytic anemia refers to both cold agglutinin disease and warm autoimmune hemolytic anemia, which affect a combined 40,000 people in the United States and Europe.

Apellis’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of Autoimmune Hemolytic Anemia

Feb 4th, 2019 - Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases through inhibition of the complement system, today announced that its C3 complement inhibitor, APL-2, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of autoimmune hemolytic an...

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura
Scully, M. et. al.

Jan 23rd, 2019 - In acquired thrombotic thrombocytopenic purpura (TTP), an immune-mediated deficiency of the von Willebrand factor–cleaving protease ADAMTS13 allows unrestrained adhesion of von Willebrand factor multimers to platelets and microthrombosis, which result in thrombocytopenia, hemolytic anemia, and tissue ischemia. Caplacizumab, an anti–von Willebrand factor humanized, bivalent variable-domain-only ...

Iron Deficiency Anemia - Signs and Symptoms

Jan 17th, 2019 - Iron-deficiency anemia is a common type of anemia that occurs if you do not have enough iron in your body. People with mild or moderate iron-deficiency anemia may not have any signs or symptoms. More severe iron-deficiency anemia may cause fatigue or tiredness, shortness of breath, or chest pain.

A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease
Howard, J et. al.

Jan 16th, 2019 - New treatments directly targeting polymerization of sickle hemoglobin (HbS), the proximate event in the pathophysiology of sickle cell disease (SCD), are needed to address the severe morbidity and early mortality associated with the disease. Voxelotor (GBT440) is a first-in-class, oral therapy specifically developed to treat SCD by modulating the affinity of hemoglobin for oxygen, thus inhibiti...

The management of primary mediastinal B‐cell lymphoma: a British Society for Haematology Good Practice Paper
Cwynarski, K. et. al.

Jan 3rd, 2019 - Primary mediastinal B‐cell lymphoma (PMBCL) represents 2–4% of non‐Hodgkin lymphomas and, whilst previously considered to be a subtype of diffuse large B‐cell lymphoma (DLBCL), gene expression profiling data has shown it to be a separate clinicopathological entity with evidence of an overlap with classic Hodgkin lymphoma (Rosenwald et al, 2003; Savage et al, 2003). Furthermore, it is immunophen...

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019

Jan 1st, 2019 - Chronic lymphocytic leukemia (CLL) is generally characterized by an indolent disease course. Histologic transformation (also known as Richter's transformation) to more aggressive lymphomas, such as diffuse large B-cell lymphoma or Hodgkin lymphoma, occurs in approximately 2% to 10% of patients and is associated with a poor prognosis. These NCCN Guidelines Insights discuss the recommendations fo...

Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation O...
Dabaja, B.

Oct 9th, 2018 - Among adult lymphoma survivors, radiation treatment techniques that increase the excess radiation dose to organs at risk (OARs) put patients at risk for increased side effects, especially late toxicities. Minimizing radiation to OARs in adults patients with Hodgkin and non-Hodgkin lymphomas involving the mediastinum is the deciding factor for the choice of treatment modality.

Vitamin B12 Deficiency Evaluation

Sep 1st, 2018 - ACASM / Pernicious Anemia Cascade Testing begins with Vitamin B12 Assay, Serum

Waldenström’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment...
Kastritis, E.

Jul 4th, 2018 - Waldenström’s macroglobulinaemia (WM) is a rare disease that accounts for 1%–2% of non-Hodgkin lymphomas. The reported age-adjusted incidence rate is 3.

Statement on Opioid Use in Patients with Hematologic Diseases and Disorders
American Society of Hematology

Apr 17th, 2018 - According to the Centers for Disease Control and Prevention, overdoses from prescription opioids in the United States have contributed to the 15-year increase in opioid overdose deaths and nearly half of all opioid overdose deaths involve a prescription opioid. The Society is alarmed about the opioid crisis, however, it is concerned about potential adverse effects that policy changes could have.

Hematology Quality Metrics
Allen, S.

Feb 20th, 2018 - These clinical performance measures are designed for individual quality improvement. Some of the measures may also be appropriate for accountability if appropriate sample sizes and implementation rules are achieved.

Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Gu...
Aapro, M.

Feb 19th, 2018 - Anaemia and iron deficiency (ID) are frequent complications in patients with solid tumours or haematological malignancies, particularly in patients treated with chemotherapeutic agents [1–3]. Frequently, anaemia is associated with fatigue, impaired physical function and reduced quality of life (QoL) [4–7].

NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018
Horwitz, S.

Jan 31st, 2018 - Natural killer (NK)/T-cell lymphomas are a rare and distinct subtype of non-Hodgkin's lymphomas. NK/T-cell lymphomas are predominantly extranodal and most of these are nasal type, often localized to the upper aerodigestive tract.

Iron Deficiency Anemia: Evaluation and Management
American Family Physician; Short, M. et. al.

Jan 14th, 2018 - Iron deficiency is the most common nutritional disorder worldwide and accounts for approximately one-half of anemia cases. The diagnosis of iron deficiency anemia is confirmed by the findings of low iron stores and a hemoglobin level two standard deviations below normal. Women should be screened during pregnancy, and children screened at one year of age. Supplemental iron may be given initially...

Treatments for Ocular Adnexal Lymphoma
Michael T. Yen

Dec 31st, 2017 - For MALT lymphomas, local control, disease-free survival, and overall survival are good with radiation treatment. The results of treatment of non-MALT lymphomas using radiotherapy also were good, but they were not as favorable as the treatment results of MALT lymphomas.

ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations fo...
Buske, C.

Nov 28th, 2017 - The European Society for Medical Oncology (ESMO) consensus conference on mature B cell lymphomas and chronic lymphocytic leukaemia (CLL) was held on 20 June 2015 in Lugano, Switzerland, and included a multidisciplinary panel of 25 leading experts. The aim of the conference was to develop recommendations on critical subjects difficult to consider in detail in the ESMO Clinical Practice Guideline.

Initial Diagnostic Work-up of Acute Leukemia: Guideline From the College of American Patholo...
Daniel A. Arber

Sep 30th, 2017 - The guideline provides a framework for the multiple steps, including laboratory testing, in the evaluation of acute leukemia samples. Some aspects of the guideline, especially molecular genetic testing in acute leukemia, are rapidly changing with new supportive literature, which will require on-going updates for the guideline to remain relevant.

Initial Diagnostic Workup of Acute Leukemia
Daniel A. Arber

Sep 30th, 2017 - Twenty-seven guideline statements were established, which ranged from recommendations on what clinical and laboratory information should be available as part of the diagnostic and prognostic evaluation of acute leukemia samples to what types of testing should be performed routinely, with recommendations on where such testing should be performed and how the results should be reported.

Iron Deficiency Anemia

Sep 7th, 2017 - What Are the Signs and Symptoms of Iron-Deficiency Anemia? Symptoms of iron-deficiency anemia are related to decreased oxygen delivery to the entire body and may include:

Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and ...
Willemze, R.

Jul 12th, 2017 - Primary cutaneous lymphomas (PCLs) are defined as non-Hodgkin lymphomas that present in the skin with no evidence of extracutaneous disease at the time of diagnosis. After gastrointestinal lymphomas, PCLs are the second most common group of extranodal non-Hodgkin lymphomas, with an estimated annual incidence of 1/100?000 in Western countries.

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
O'Donnell, M.,et al

Jun 30th, 2017 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and provides recommendations on the workup, diagnostic evaluation, and treatment options for younger (age <60 years) and older (age ≥60 years) adult patients.

Pain Management in Vaso-occlusive Sickle Cell Crisis
Amani Mahdi

Apr 10th, 2017 - To optimize patient care, considerable effort must be directed toward understanding the pathophysiology of SCD, appreciating the severity of each episode, and anticipating the likelihood of VOC recurrence. In addition, the patient's age, comorbidities, access to follow-up care, and compliance with medical instructions are all critical factors in achieving pain control.

Initial Diagnostic Workup of Acute Leukemia: ASH Guideline
American Society of Hematology

Feb 28th, 2017 - Guide to intial diagnostic workup of acute leukemia.

ESMO consensus conference on malignant lymphoma: general perspectives and recommendations fo...
Ladetto, M.

Dec 21st, 2016 - The European Society for Medical Oncology (ESMO) consensus conference on mature B-cell lymphomas and chronic lymphocytic leukaemia (CLL) was held on 20 June 2015 in Lugano, Switzerland, and included a multidisciplinary panel of 25 leading experts. The aim of the conference was to develop recommendations on critical subjects difficult to consider in detail in the ESMO Clinical Practice Guideline.

Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ES...
Vitolo, U.

Jul 3rd, 2016 - The aim of these guidelines is to provide practical clinical guidance and recommendations to clinicians to manage diffuse large B-cell lymphomas (DLBCLs) that arise in extranodal sites. DLBCL may arise in virtually any extranodal sites, but the majority of these are treated as the nodal counterpart, i.

The role of endoscopy in the management of suspected small-bowel bleeding
Suryakanth R. Gurudu

Jun 29th, 2016 - Obscure GI bleeding (OGIB) has been defined as overt or occult bleeding of unknown origin that persists or recurs after an initial negative bidirectional endoscopic evaluation including ileocolonoscopy and EGD. Overt OGIB refers to visible bleeding (eg, melena or hematochezia), whereas occult OGIB refers to cases of fecal occult blood positivity and/or unexplained iron deficiency anemia.

Daily Iron Supplementation in Adult Women and Adolescent Girls

Apr 3rd, 2016 - This guideline provides a global, evidence-informed recommendation on daily iron supplementation in menstruating adult women and adolescents, as a public-health intervention for the prevention of anaemia and iron deficiency. The guideline aims to help Member States and their partners in their efforts to make informed decisions on the appropriate nutrition actions to achieve the Sustainable Deve.

Daily Iron Supplementation in Infants and Children

Mar 29th, 2016 - This guideline provides global, evidence-informed recommendations on daily iron supplementation in infants and children, as a public-health intervention for the prevention of anaemia and iron deficiency. It includes recommendations for iron supplementation in countries where malaria is prevalent.

Iron Supplementation in Postpartum Women

Mar 29th, 2016 - Iron deficiency is one of the most common forms of nutritional deficiencies, particularly among vulnerable groups such as women, children and low-income populations. Iron deficiency often precedes anaemia, and anaemia during pregnancy is one of the strongest predictors of anaemia during the postpartum period, beginning just after childbirth throughout the subsequent 6 weeks.

Pediatric Pulmonary Hypertension
Steven H. Abman

Mar 14th, 2016 - Pulmonary hypertension is associated with diverse cardiac, pulmonary, and systemic diseases in neonates, infants, and older children and contributes to significant morbidity and mortality. However, current approaches to caring for pediatric patients with pulmonary hypertension have been limited by the lack of consensus guidelines from experts in the field.

Practical Approach to Detection and Management of Chronic Kidney Disease for the Primary Care Clinician
The American Journal of Medicine; Vassalotti, J. et. al.

Feb 1st, 2016 - A panel of internists and nephrologists developed this practical approach for the Kidney Disease Outcomes Quality Initiative to guide assessment and care of chronic kidney disease (CKD) by primary care clinicians. Chronic kidney disease is defined as a glomerular filtration rate (GFR) <60 mL/min/1.73 m2 and/or markers of kidney damage for at least 3 months. In clinical practice the most comm...

Diffuse Large B-Cell Lymphoma Version 1.2016
Zelenetz, A.,et al

Jan 31st, 2016 - Diffuse large B-cell lymphomas (DLBCL) are now considered a heterogeneous group of distinct molecular subtypes (germinal center B-cell DLBCL, activated B-cell DLBCL, and primary mediastinal large B-cell lymphoma (PMBL) with varied natural history and response to therapy. In addition, a subset of patients with DLBCL have concurrent MYC and/or BCL2 gene rearrangements (double-hit lymphomas; DHL).

Iron Deficiency Anemia in Pregnant Women: Screening and Supplementation
US Preventive Services Task Force

Aug 31st, 2015 - The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for iron deficiency anemia in pregnant women to prevent adverse maternal health and birth outcomes. The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of routine iron supplementation for pregnant women to prevent adverse.

Iron Deficiency Anemia in Young Children: Screening
US Preventive Services Task Force

Aug 31st, 2015 - The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for iron deficiency anemia in children ages 6 to 24 months.

Practice Guidelines for Perioperative Blood Management
American Society of Anesthesiologists (ASA)

Jan 31st, 2015 - The purposes of these updated Guidelines are to improve the perioperative management of blood transfusion and adjuvant therapies and to reduce the risk of adverse outcomes associated with transfusions, bleeding, or anemia.

Basic Laboratory Tests Complete Blood Counts (CBC)

Jan 11th, 2015 - Hemoglobin (Hb) is a measurement of the amount of the oxygen carrying protein hemoglobin per unit volume present in the blood. Hemoglobin is found within red blood cells and gives these cells their characteristic red color. Hemoglobin levels are generally higher in males than females. A reduction in the hemoglobin level is called anemia and may result from excess blood loss, premature destru...

Health Maintenance and Management of Chronic Complications of Sickle Cell Disease: ASH Guide...
American Society of Hematology

Oct 31st, 2014 - Guide for Health Maintenance and Management of Chronic Complications of Sickle Cell Disease.

Hydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease: ASH Guideline
American Society of Hematology

Oct 31st, 2014 - Guide for Hydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease.

Management of Acute Complications of Sickle Cell Disease: ASH Guideline
American Society of Hematology

Oct 31st, 2014 - Guide for management of acute complications of sickle cell disease.